http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kim, Seung Cheol,Song, Yong Sang,Kim, Young-Tae,Kim, Young Tak,Ryu, Ki-Sung,Gunapalaiah, Bhavyashree,Bi, Dan,Bock, Hans L,Park, Jong-Sup Korean Society of Gynecologic Oncology and Colposc 2011 Journal of Gynecologic Oncology Vol.22 No.2
<P><B>Objective</B></P><P>The study assessed the immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Korean women aged 15-25 years.</P><P><B>Methods</B></P><P>Phase IIIB, double-blind, randomised (2:1), multi-centre trial was conducted in Korea from June 2007 to March 2008. The study enrolled 225 women in the HPV (N=149) and placebo (N=76) groups who received three doses of HPV-16/18 AS04-adjuvanted vaccine or placebo (aluminium hydroxide) administered intramuscularly at 0, 1, and 6 months and were followed until one month post-dose 3. Serum samples were collected pre-vaccination and one month post-dose 3. Safety and reactogenicity data were collected throughout.</P><P><B>Results</B></P><P>In this trial, 208 women completed the study (141 in HPV group; 67 in placebo group). At month 7, all initially seronegative women had seroconverted for HPV-16 and HPV-18 antibodies with anti-HPV-16 and anti-HPV-18 geometric mean titres of 9,351.4 El.U/mL (95% CI, 8,145.5 to 10,735.8) and 4204.1 El.U/mL (95% CI, 3,626.5 to 4,873.6), respectively. Initially seropositive women showed similar increase in geometric mean titre levels. Compliance to the three dose vaccination course was 95.3% in HPV and 89.5% in placebo group. Solicited local (pain) and general (fatigue, myalgia or headache) symptoms were commonly reported in both groups. Three serious adverse events were reported (two in HPV group; one in placebo group), all unrelated to vaccination by the investigator; all recovered.</P><P><B>Conclusion</B></P><P>The HPV-16/18 AS04-adjuvanted vaccine was highly immunogenic with a clinically acceptable safety profile in Korean women. This study was in line with previous global studies in Europe, North America, and Brazil. (ClinicalTrials.gov number, NCT 00485732.)</P>
Robotic single-port transumbilical total hysterectomy: a pilot study
Nam, Eun Ji,Kim, Sang Wun,Lee, Maria,Yim, Ga Won,Paek, Ji Heum,Lee, San Hui,Kim, Sunghoon,Kim, Jae Hoon,Kim, Jae Wook,Kim, Young Tae Korean Society of Gynecologic Oncology and Colposc 2011 Journal of Gynecologic Oncology Vol.22 No.2
<P><B>Objective</B></P><P>To evaluate the feasibility of robotic single-port transumbilical total hysterectomy using a home-made surgical glove port system.</P><P><B>Methods</B></P><P>We retrospectively reviewed the medical records of patients who underwent robotic single-port transumbilical total hysterectomy between January 2010 and July 2010. All surgical procedures were performed through a single 3-4-cm umbilical incision, with a multi-channel system consisting of a wound retractor, a surgical glove, and two 10/12-mm and two 8 mm trocars.</P><P><B>Results</B></P><P>Seven patients were treated with robotic single-port transumbilical total hysterectomy. Procedures included total hysterectomy due to benign gynecological disease (n=5), extra-fascial hysterectomy due to carcinoma <I>in situ</I> of the cervix (n=1), and radical hysterectomy due to cervical cancer IB1 (n=1). The median total operative time was 109 minutes (range, 105 to 311 minutes), the median blood loss was 100 mL (range, 10 to 750 mL), and the median weight of the resected uteri was 200 g (range, 40 to 310 g). One benign case was converted to 3-port robotic surgery due to severe pelvic adhesions, and no post-operative complications occurred.</P><P><B>Conclusion</B></P><P>Robotic single-port transumbilical total hysterectomy is technically feasible in selected patients with gynecological disease. Robotics may enhance surgical skills during single-port transumbilical hysterectomy, especially in patients with gynecologic cancers.</P>
Lee, Si Won,Lee, Soo Yoon,Lee, Sa Ra,Ju, Woong,Kim, Seung Cheol Korean society of gynecologic oncology and colposc 2010 Journal of Gynecologic Oncology Vol.21 No.3
<P>The goal of this study was to investigate the relationship between plasma levels of insulin-like growth factors-1 (IGF-1) and IGF-binding protein-3 (IGFBP-3) and the risk for cervical intraepithelial neoplasia (CIN) and cervical cancer.</P>
Wine drinking and epithelial ovarian cancer risk: a meta-analysis.
Kim, Hee Seung,Kim, Jae Weon,Shouten, Leo J,Larsson, Susanna C,Chung, Hyun Hoon,Kim, Yong Beom,Ju, Woong,Park, Noh Hyun,Song, Yong Sang,Kim, Seung Cheol,Kang, Soon-Beom Korean society of gynecologic oncology and colposc 2010 Journal of Gynecologic Oncology Vol.21 No.2
<P>Wine has been the focus in the prevention of epithelial ovarian cancer (EOC) development because resveratrol abundant in wine has anti-carcinogenic properties. However, epidemiologic results have been heterogenous in the chemopreventive effect of wine on the development of EOC. Thus, we performed a meta-analysis for comparing EOC risk between wine and never drinkers using previous related studies.</P>
Kang, Sokbom,Kim, Tae-Joong,Seo, Sang-Soo,Kim, Byoung-Gie,Bae, Duk-Soo,Park, Sang-Yoon Korean Society of Gynecologic Oncology and Colposc 2011 Journal of Gynecologic Oncology Vol.22 No.4
<P><B>Objective</B></P><P>We aimed to determine the ideal cut-off of nadir serum CA-125 level for prediction of progression free survival.</P><P><B>Methods</B></P><P>Among 267 patients who achieved complete remission after chemotherapy, the correlation between nadir CA-125 and progression free survival were compared among the subgroups classified according to the distribution of CA-125. The diagnostic odds ratio and area under the receiver operator characteristics curve were compared at various cut-off points.</P><P><B>Results</B></P><P>The nadir CA-125 levels did not have prognostic value under 12 U/mL (to 75 percentile). In contrast, they were significantly correlated with progression free survival only when the CA-125 level was greater than 12, which was 75 percentile (p=0.034). In predicting progression free survival <6 and 12 months, the cut-off value of 18 (90 percentile) showed superior diagnostic performance over 10 or 12 U/mL. Compared with patients who showed nadir levels between 0 and 12 U/mL (0 to 75 percentile), those with nadir >18 U/mL showed a hazard ratio of 2.85 (95% confidence interval, 1.70 to 4.76; p<0.001); patients with nadir levels between 18 and 12 U/mL showed a the hazard ratio of 1.68 (95% confidence interval, 1.11 to 2.56; p=0.015) compared with those whose nadir levels were under 12 U/mL.</P><P><B>Conclusion</B></P><P>The predictive power of the traditional cut-off of 10 U/mL to classify a risk group or to identify high risk patients was unsatisfactory. The optimal diagnostic performance was observed at the cut-off of 18 U/mL and this can be proposed to dichotomize cut-off values to predict outcomes among individual patients.</P>
Plasma proteomic analysis of patients with squamous cell carcinoma of the uterine cervix
Jeong, Dae Hoon,Kim, Hyoung Kyu,Prince, Abd-EI Bary,Lee, Dae Sim,Kim, Young Nam,Han, Jin,Kim, Ki Tae Korean society of gynecologic oncology and colposc 2008 Journal of Gynecologic Oncology Vol.19 No.3
Objective: To compare plasma protein expression between patients with squamous cell carcinoma (SCC) of the cervix and normal controls. Methods: Plasma samples from patients with benign gynecological disease (normal cervix, n=6) and cervical cancer (SCC, n=6) were subjected to plasma proteomic analysis using two dimensional gel electrophoresis (2-DE) and matrix-assisted laser desorption/ionization mass spectroscopy (MALDI-MS). Western blotting and immunoturbidimetric assay were performed to validate the results of 2-DE. Results: Eight proteins showed differential expression between controls and SCC patients; six (ceruloplasmin, complement C3, afamin precursor, alpha-1-B-glycoprotein, transferrin, alpha-fibrinogen precursor) were up-regulated, while two (chain A, crystal structure of antithrombin and apolipoprotein A-IV precursor) were down-regulated in the plasma of SCC patients. Western blotting analysis revealed significant elevation of ceruloplasmin, complement C3, afamin, and alpha-1-B-glycoprotein in the plasma of SCC patients in comparison to controls. Immunoturbidimetric assay of a larger group confirmed the results of 2-DE and Western blotting, and showed that ceruloplasmin and complement C3 were significantly elevated in the plasma of SCC patients in comparison with controls and patients with carcinoma in situ (CIS) of the uterine cervix. Conclusion: Plasma protein expression determined using 2-DE and MALDI-MS will give a chance to identify tumor-specific biomarkers for SCC of the cervix.